Back to School: How biopharma can reboot drug development. Access exclusive analysis here
DNA reported preliminary data from its 104-patient, open label study of rhuMAb-VEGF in combination with 5-fluorouracil (5-FU)/leucovorin, showing
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury